1. Home
  2. ENGN vs WEA Comparison

ENGN vs WEA Comparison

Compare ENGN & WEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

SELL

Current Price

$1.95

Market Cap

117.2M

Sector

N/A

ML Signal

SELL

Logo Western Asset Bond Fund Share of Beneficial Interest

WEA

Western Asset Bond Fund Share of Beneficial Interest

SELL

Current Price

$9.65

Market Cap

114.4M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
ENGN
WEA
Founded
1999
2002
Country
Canada
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
117.2M
114.4M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
ENGN
WEA
Price
$1.95
$9.65
Analyst Decision
Buy
Analyst Count
9
0
Target Price
★ $4.29
N/A
AVG Volume (30 Days)
★ 1.5M
62.2K
Earning Date
12-21-2026
01-01-0001
Dividend Yield
N/A
★ 7.87%
EPS Growth
★ 56.85
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.40
$9.52
52 Week High
$12.25
$11.42

Technical Indicators

Market Signals
Indicator
ENGN
WEA
Relative Strength Index (RSI) 55.31 40.68
Support Level $1.61 $9.55
Resistance Level $8.93 $9.86
Average True Range (ATR) 0.18 0.09
MACD 0.07 0.00
Stochastic Oscillator 47.17 6.00

Price Performance

Historical Comparison
ENGN
WEA

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

About WEA Western Asset Bond Fund Share of Beneficial Interest

Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The fund invests in bonds of companies operating in different sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.

Share on Social Networks: